India's Venus Remedies gains on exclusive India rights for UK co's drug

Venus Remedies

25/02/2025 08:12

** Venus Remedies  VENR.NS  climbs as much as 4.4% to 320
rupees
    ** Pharma firm gets exclusive in-licensing rights from
UK-based Infex Therapeutics to develop, market anti-infection
drug MET-X in India
    ** No financial details have been disclosed
    ** Stock last up 2.6%, trimming YTD losses to ~4%

 (Reporting by Manvi Pant in Bengaluru)
 ((Manvi.Pant@thomsonreuters.com; +918447554364;))